Maimon Carole Ben - Jan 31, 2023 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role: President and CEO, Director
Signature: /s/ Jennifer Johansson, Attorney-in-fact
Stock symbol: LRMR
Transactions as of: Jan 31, 2023
Transactions value $: $0
Form type: 4
Date filed: 2/2/2023, 07:15 PM
Previous filing: Sep 19, 2022
Next filing: May 18, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LRMR	Common Stock	Award	$0	+205K	+360.73%	$0.00	262K	Jan 31, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LRMR	Stock Option (Right to Buy)	Award	$0	+325K		$0.00	325K	Jan 31, 2023	Common Stock	325K	$4.94	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2	The option vests 25% on January 31, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.